Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/225—Polycarboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
  • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

• This invention relates to treatment of chronic myeloid leukemia (CML) by a composition comprising analogs of chlorogenic acid and/or its salts such as sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.
• CML chronic myeloid leukemia
• AML Acute Myeloid Leukemia
• CML Chronic Myeloid Leukemia
• AML is characterized by an increase in the number of myeloid cells in the bone marrow and an arrest in their maturation.
• AML is approximately 2.4 per 100,000 and it increases progressively with age, to a peak of 12.6 per 100,000 adults 65 years of age or older.
• the CML is a malignant clonal disorder of hematopoietic stem cells.
• the median age at presentation is 53 years, but it occurs at all age groups, including children.
• the natural history of CML is progression from a benign chronic phase to a rapidly fatal blast crisis within three to five years or even earlier.
• CD33 represents a specific and useful marker in the process of myeloid cell differentiation (2).
• Recent reports suggest that engagement of CD33 by monoclonal antibody induced apoptosis leading to growth inhibition of proliferation of AML and CML cells in vitro (2,3).
• Exploiting the myeloid specific expression of CD33 humanized anti-CD33 monoclonal antibody conjugated with anti- cancer drug has been tried in AML patients with significant success (4).
• lymphoid leukemia is also subdivided in two groups: acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
• ALL acute lymphocytic leukemia
• CLL chronic lymphocytic leukemia
• Lymphoid leukemia may affect both T and B cell lineages and are prevalent in children. With the extracts from Piper betel leaves anti- myeloid activity was claimed earlier (Patent filed no. PCT/TNOO/00118 dated December 12, 2000). Two compounds isolated from Piper betel extract also showed anti myeloid leukemic activity. One compound was 3-O-Coumaryl quinic acid (patent application no. US 60/384, 163 dated 31.05.2002). The other compound was Chlorogenic acid (patent application no. US 60/393750 dated 08.07.2002).
• Chlorogenic acid (Chi) is known to have anti-allergic activity (5). Chi also inhibits hepatic and renal glucose-6-phosphatase systems (6). Chi is an inhibitor of epidermal lypoxygenase activity and TPA-induced ear inflammation (7). Chi also renders inhibitory effects on TPA-induced tumor promotion in mouse skin (7). Anti-HIN activity of Chi has also been reported (8).
• Bcr-Abl constitutively active tyrosine kinase
• CML chronic myelogenous leukemia
• Highly potent small molecules are known to inhibit Bcr-Abl dependent cell growith 10 11 .
• Piper betel inhibits Abl protein tyrosine kinase triggering apoptosis of Bcr-Abl expressing CML cell line K562. Elucidation of structure identifies this molecule as chlorogenic acid.
• the main object of the invention is to provide a pharmaceutical composition comprising analogs of chlorogenic acid and/or its salts.
• Another object of the present invention is to provide a pharmaceutical composition comprising analogs of chlorogenic acid and/or its salts for treating chronic myeloid leukemia.
• Another object of the invention is to provide pharmaceutical composition
• salts of chlorogenic acid and / or its salts such as sodium chlorogenate (NaChl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs for the treatment of chronic myeloid leukemia.
• Another object of the invention is to provide a new use of the compound sodium chlorogenate (NaChl) prepared from Chlorogenic acid (Chi) isolated from the Piper betel leaf extract or from any other sources for the treatment of chronic myeloid leukemia.
• Another objective of the invention is to provide a new pharmaceutical composition comprising a carrier along with the compound sodium chlorogenate for the treatment of chronic myeloid leukemia.
• Yet another objective of the invention is to provide a process for the preparation of sodium chlorogenate from Chlorogenic acid to treat CML.
• Yet another objective of the invention is to provide a simplified method of preparation of NaChl from Chlorogenic acid which was isolated from all plant parts of Piper betel possessing biological activities relevant to the treatment of CML.
• Yet another objective of the invention is to provide sodium salt of Chlorogenic acid a herbal product from leaves or any other plant parts of Piper betel for the treatment of CML.
• the present provides a pharmaceutical composition for the treatment of chronic myeloid leukemia (CML) by a composition comprising analogs of chlorogenic acid and/or its salts such as sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.
• CML chronic myeloid leukemia
• Na-Chl sodium chlorogenate
• the present invention provides a pharmaceutical composition, which kills myeloid cancer cells leaving other normal cells unaffected.
• Chronic myeloid leukemia is lethal, there is no drug directing towards the destruction of the leukemic cells, and these cells poorly respond to chemotherapy which is always non-specific thus adversely affecting normal cells.
• the present invention provides a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid and/or its salts along with pharmaceutically acceptable additives.
• the said composition is also useful in treating diseases caused by over expression of Abl type of kinase
• the analogs of chlorogenic is selected from a group consisting of neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O- Caffeoyl quinic acid), 3-O-(3'-methylcaffeoyl) quinic acid and 5 -O-(Caffeoyl-4' -methyl) quinic acid.
• analogs of chlorogenic acid are obtained either from natural sources or synthetically prepared.
• the salt of chlorogenic acid analog is selected from sodium, potassium and ammonium.
• the additive is selected from a group consisting of nutrients such as proteins, carbohydrates, sugars, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste and/or pharmaceutically acceptable carriers, excipient, diluents or solvents.
• nutrients such as proteins, carbohydrates, sugars, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste and/or pharmaceutically acceptable carriers, excipient, diluents or solvents.
• the composition may administered through oral, intravenous, intramuscular or subcutaneous routes.
• the said composition is administered at a dose level ranging between about 1 and 100 mg per kg body weight/day, preferably in the range of 1 to 25 mg/kg body weight.
• the said composition may be administered for period ranging between at least four weeks and up to twelve weeks, and in case of relapse it can again can be administered to the subject without any toxicity.
• the said composition inhibits the growth of leukemic cell types K562. and Molt-4.
• the said composition inhibits the growth of leukemic cell types Molt-4.
• composition, IC 50 value for in vitro activity against K562 cells of concentration of 10 /well is up to 27.0 nanomole/ml.
• the IC50 values for chlorogenic acid and sodium chlorogenate on K562 cells is 13.5 and 27.0 ⁇ m/10 4 cells respectively (Fig 2C & 2D).
• Another embodiment the acute toxicity of sodium chlorogenate in mouse model, wherein the compound is non-toxic up to a dose level of 2gm/kg body weight in oral route.
• Fig. 1 Structure of sodium chlorogenate, one of the salts of chlorogenic acid..
• Fig. 2 Purification of chlorogenic acid from Piper betel leaves and its effects on cell lines and Ph + " CML patients' PBMC in vitro.
• the flow diagram of purification is shown.
• the structure of peak 09 isolated from fraction E by HPLC was deduced as chlorogenic acid by spectroscopic methods (IR, NMR, 13 CNMR, FABMS).
• Cell count assays were performed by plating cells in the presence of regular growth medium with or without indicated amount of extract (a), fraction (b), purified compound (c) and its sodium salt (d).
• Example 2 The Chlorogenic acid is available in the market in the pure form. The Chlorogenic acid (1 gm) was hand shaken with sodium hydrogen carbonate (024 g in 5 ml of water) solution. The solution was lyophilised to pure sodium chlogogenate (1.12 gm) and was tested for biological activity. Sodium chlorogenate prepared from chlorogenic acid which was either isolated from Piper betel or obtain commercially have similar structure and activity.
• Example 3 The Chlorogenic acid is available in the market in the pure form. The Chlorogenic acid (1 gm) was hand shaken with sodium hydrogen carbonate (024 g in 5 ml of water) solution. The solution was lyophilised to pure sodium chlogogenate (1.12 gm) and was tested for biological activity. Sodium chlorogenate prepared from chlorogenic acid which was either isolated from Piper betel or obtain commercially have similar structure and activity.
• Example 3 The Chlorogenic acid is available in the market in the pure form. The Chlorogenic acid (1 gm) was hand shaken with sodium hydrogen
• Bcr-Abl positive CML cell line K562
• peripheral blood cells of CML patients Bcr-Abl-negative ALL cell line (Molt-4)
• peripheral blood cells of CML patients Bcr-Abl-negative ALL cell line (Molt-4)
• Cell count assays were performed by plating cells in the presence of regular growth medium with or without indicated amount of extract, fraction, purified compound and its sodium salt. Each day, viable cells were counted as assessed by exclusion of trypan blue.
• NaChl has no effect on Bcr-Abl negative CML patients PBMC (Fig. 2e).
• Phase contrast microscopy indicates that NaChl induces mo ⁇ hological changes (nuclear condensation) in K562 cells, sign of apoptosis (Fig. 2f).
• the IC50 values for chlorogenic acid and sodium chlorogenate on K562 cells is 13.5 and 27.0 ⁇ m/10 4 cells respectively Fig 2C & 2D.
• the compound is non-toxic upto the dose level of 2gm/kg body weight in oral route.
• Results of examples 5 to 9 Treatment with NaChl did not induce apoptosis in Molt-4 cells, normal PBMC or PBMC of Bcr-Abl negative CML patients. In contrast, the same treatment cause an increase in apoptosis in Bcr-Abl positive K562 cells and PBMC of Bcr-Abl positive CML patients (Fig. 3 a). DNA cell cycle analysis also indicates that NaChl induces cell cycle arrest followed by breakdown of DNA in Bcr-Abl positive CML cell line K562 cells and PBMC of Bcr-Abl positive CML patients (Fig. 3b).
• FIG. 3c Confocal microscopy indicating positive Annexin V staining in K562 cells but not in Molt-4 cells after treatment with NaChl is shown in Fig. 3c.
• NaChl inhibits phosphorilation of Bcr-Abl protein tyrosine kinase without affecting the expression of Abl protein level. This is evident by flow cytometric detection of phospho-c- Abl status (Fig. 4a), and by immunoblot detection (Fig.
• Fig.-4d shows that chlorogenic acid (Chi, Panel-B) can fit into the binding pocket of Abl kinase in the inactive conformation in a position similar to that of Gleevec (Panel-A) and in the active conformation (Panel-D) similar to that of PD173955 (Panel-C).
• Empirical energies associated with the docking of the ligand into the binding pockets of the active and inactive conformations of the kinase are negative and comparable to those of other small molecule inhibitors e.g. Gleevec and PD 173955 indicating stable complex formation.
• Chi Binding energies of Chi in charged and neutral forms are different and the magnitude of electrical interactions depends on the electrical state of the molecule unlike the neutral inhibitors.
• Modeling studies indicate that Chi can bind to both the active and inactive conformations of the kinase like PD173955.
• Chi forms a number of hydrogen bonds with the surrounding residues as found in the complex of Gleevec while keeping some of the hydrophobic interactions intact.
• Chi forms higher number hydrogen bonds while maintaining similar number of hydrophobic contacts. It has been found that the aromatic hydroxyl groups of Chi forms a network of hydrogen bonds in the binding pocket suggesting the importance of these groups in the complex formation.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Molecular Biology (AREA)
• Medical Informatics (AREA)
• Alternative & Traditional Medicine (AREA)
• Oncology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=30118032

Family Applications (1)

Country Status (4)

Families Citing this family (4)

Family Cites Families (4)

• 2003
  • 2003-01-10 WO PCT/IB2003/000044 patent/WO2004004708A1/en not_active Ceased
  • 2003-01-10 JP JP2004519034A patent/JP2006519752A/ja active Pending
  • 2003-01-10 AU AU2003201062A patent/AU2003201062A1/en not_active Abandoned
  • 2003-01-10 EP EP03762826A patent/EP1524973A1/de not_active Withdrawn

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events